Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
Authors
Keywords
Colorectal cancer, <em class=EmphasisTypeItalic >KRAS</em>, <em class=EmphasisTypeItalic >NRAS</em>, <em class=EmphasisTypeItalic >BRAF</em>, <em class=EmphasisTypeItalic >PIC3CA</em>
Journal
Journal of Translational Medicine
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-10-13
DOI
10.1186/s12967-016-1053-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS
- (2016) Jiang Liu et al. OncoTargets and Therapy
- Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials
- (2016) Lizhen Zhu et al. PLoS One
- Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer
- (2015) Luisa Foltran et al. Future Oncology
- Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway
- (2015) Eiji Sakai et al. INTERNATIONAL JOURNAL OF CANCER
- Prognostic value ofKRASandBRAFmutations in curatively resected colorectal cancer
- (2015) Shigenori Kadowaki WORLD JOURNAL OF GASTROENTEROLOGY
- New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
- (2015) Giuseppe Bronte et al. Oncotarget
- The predictive value ofKRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
- (2014) Christina Therkildsen et al. ACTA ONCOLOGICA
- BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients
- (2014) Jing Chen et al. BMC CANCER
- The MAPK pathway across different malignancies: A new perspective
- (2014) Mauricio Burotto et al. CANCER
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
- (2013) George Pentheroudakis et al. BMC CANCER
- The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
- (2013) V Eklöf et al. BRITISH JOURNAL OF CANCER
- Unstable genomes elevate transcriptome dynamics
- (2013) Joshua B. Stevens et al. INTERNATIONAL JOURNAL OF CANCER
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis
- (2013) Zi-Xu Yuan et al. PLoS One
- Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
- (2012) Y. Imamura et al. CLINICAL CANCER RESEARCH
- Is K-ras Gene Mutation a Prognostic Factor for Colorectal Cancer
- (2012) JiaoJiao Ren et al. DISEASES OF THE COLON & RECTUM
- Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia
- (2012) Grazia Palomba et al. Journal of Translational Medicine
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
- (2011) T Yokota et al. BRITISH JOURNAL OF CANCER
- Mutations and epimutations in the origin of cancer
- (2011) Päivi Peltomäki EXPERIMENTAL CELL RESEARCH
- Global Patterns of Cancer Incidence and Mortality Rates and Trends
- (2010) A. Jemal et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
- (2010) Jolien Tol et al. EUROPEAN JOURNAL OF CANCER
- Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies
- (2010) Li-Xin Qiu et al. EUROPEAN JOURNAL OF CANCER
- Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer
- (2010) Inti Zlobec et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
- (2010) Alberto Bardelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy
- (2009) Milena Casula et al. BMC CANCER
- A role of BRCA1 and BRCA2germline mutations in breast cancer susceptibility within Sardinian population
- (2009) Grazia Palomba et al. BMC CANCER
- Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
- (2009) J Souglakos et al. BRITISH JOURNAL OF CANCER
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CAMutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
- (2009) Shuji Ogino et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAFMutation in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer
- (2009) Winder ONCOLOGY REPORTS
- Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases
- (2008) L. Barault et al. CANCER RESEARCH
- CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
- (2008) S. Ogino et al. GUT
- Epigenetics in Cancer
- (2008) Manel Esteller NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now